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A 51-year-old woman came to the office with a 9month history of aural fullness and hearing loss in the left ear that appeared to be secondary to a healed perforation. Her condit ion had improved 2 weeks after the onset of these symptoms, but 1 month later she awoke in the middle of the night with palpitations and a cold sweat ; these symptoms were soon follow ed by nausea and a sensation that "the room was moving." The moving sen-sation lasted approxi mately 2 hours. One week later, she experienced a similar spell and stayed home for several days. During that time she felt lighthe aded and nauseous. Another week later, she woke up again feeling 1ightheaded; as the day went on, she began to feel worse and she eventually experienced nausea and vomiting on her way home from work.
The patient was treated with meclizine, but 8 days later ice) and250 mglkg (rats) we readministered for up to 2 years, there was noevidence had anycarci nogenicor tumorigenic effects in these species. Nolongtermstudies of suspension have been pertormed to evaluate carcinogenicpotential. Fertil ity studies pertormed in rats at oral doses of ciprot loxacin up to 100 mgikg/day reveal ed no evidence ot impairment. This would be over 1000 times themaxi mum recommended clinical dose of ototopical ciprofloxacinbased uponbody surtace area, assumingtotalabsorptionofciprot loxacinfromthe ear ofa patient treated wi th CIPRO' HC OTICtwice perday. Long term studies have not been pertormed to evaluate the carcinogenic potential or the effect on fertil ityoftopical hydrocort isone. Mutagenicitystudies wit h hydrocorti sonewerenegative. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproductionstudies have been pert ormed in ratsand mice usi ngoral doses of upto 100mglkg andIV doses upto 30 mglkg and have revealed no evidence of harm to the fetus asa resul t of ciprolloxacin. In rabbi ts, ciprofloxacin (30and 100mgJkg orally) produced gastroi ntestinal dist urbances resulting inmaternal weight lossandan increased inci dence of abortion, but noteratogenici tywas observed at either dose. After intravenousadminist rationof doses upto20 mglkg, no maternaltoxicity was produced intherabbit, and no embryotoxicity or teratogenicitywas observed. Corticosteroids are generall y teratogenic in laboratory ani ma ls when admi nistered systemically at rel ativel y low dosage levels. The more potent corticosteroidshave been shown to beteratogenicafter dermalapplicationin laboratoryani mals. Animal reproduction studies have not been conducted wit h CIPRO' HC OTIC. Noadequate and well controlled studies have been pertormed in pregnant women. Caution should be exercised when CIPRO' HCOTICis used by a pregnantwoman. Nursing Mothers: Ci prolloxacinis excreted in humanmi lk with systemic use. It is notknown whether ciprofloxacin is excreted in humann:'ilk toll owingt opical otic administration. Becauseof the potentialtor senousadverse reacnons Innursing Infants, acecisionshoul d be madewhether todiscontinuenursing or to di scontinuethedrug, taking Into account theimportanceot thedrug to the mother. Pediatric use: The safety and efficacy of CIPRO' HC OTIC have been established in pediatric patients 2 years and older (1 31 patients) in adequate and well-controlled clinical trial s. Al though no data are available on patients less thanage 2 years, there are no known safety concernsor differences in thẽ~: ' B' 6~A~c :~~8~~~I~~~~~~IO~~h woul dprecludeuseot thi sproduct in patientsone year andolder.
AOVERSE REACTIONS
In Phase 3 cli nical trials, a total of 564 patients weretreated with CIPRO' HCOTIC. Adverse events wit h at least remote relationshi p to treatment incl uded headache (1.2%) and pruritus(0.4%). The tollowing treatment-relat ed adverse eventswereeachreport ed inasinglepatient: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash, urncana, andalopecia. NDC0065·B531-10 CIPRO' isa registered trademark of BayerAG. Licensed byBayer AG Manufactured byBayer Corporation Rx Only U.S. Pat. Nos. 4, 670, 444; 4, 644, 902; 5, 843, 930;  
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she experienced another midnight episode of nausea and vomiting that lasted 5 hours. Computed tomography (CT) detected no evidence of an abnormality. She was prescribed triamterene/hydrochlorothiazide, and for the next 5 months she experienced no significant spells (although she did report intermittent lightheadedness and quea siness). However, she subsequently experienced a spell of lightheadedness and nausea while at work, and this was followed 1 week later by anothe r spell at work that lasted 5 hour s. Magnetic resonance imaging results on two occasions were negative.
She experienced another major spell 1 week prior to her initial office visit. She reported that her hearing loss on the left was fluctuating and that her aural fullness on the left "comes and goes with the hearing loss." She reported no tinnitus. Her family history was significant for dizziness in three siblings .
Examination of the ears revealed anterior tympanosclerosis on the left. Audiology reflected a slight drop of 6 and 8 kHz on the left. Acoustic immittance revealed shallow tympanometry. Electronystagmography detected a slight right-beating nystagmus in the supine and leftlateral positions . The alternate binaural bithermal caloric test demonstrated a less intense (but not clearly hypoactive) response from the warm stimulus on the left. The reduced vestibul ar response (RVR) was 13% left, and the direction al preponderance was 18% right-beating. Simultaneous binaural bithermal testing revealed a type 2 response with an RVR left. Ultrathin CT (pixel size : 0.07 mm) of the temporal bones detected signs consi stent with otosclerosis, A 5-hour glucose tolerance test found an exaggerated blood sugar respon se and hyperinsulinemia, She also had an elevated triglyceride level, which was con sistent with her hyperglycemia and was reflective of a diet too high in carbohydrates . She was prescribed a bisphosphonate, a calcium supplement, fluoride, and diet therapy to address her metabolic factor s,She has been free of dizzines s ever since .
This patient apparently had symptoms of hydrops in the left ear. The simultaneous binaural bithermal stimulus induced responses that were consistent with a vestibul ar abnormality in the left ear and that were not evident on alternate binaural bithermal stimulus. The immitt ance findings were consistent with tympanosclerosis and otosclerosis, Her family history hinted at a genetic tendency toward dizziness, which might also be indicative of otosclerosi s, Finally , her metabolic status might have had an imp act on the function of her inner ear.
